1XRAY Stock Chart & Stats
€9.58
€0.07(0.56%)
At close: 4:00 PM EDT
€9.58
€0.07(0.56%)
Day’s Range― - ―
52-Week Range€5.00 - €18.00
Previous CloseN/A
Volume0.00
Average Volume (3M)104.00
Market Cap
€1.76B
Enterprise Value€4.20K
Total Cash (Recent Filing)€239.00M
Total Debt (Recent Filing)€2.31B
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Oct 29, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding199,353,880
10 Day Avg. Volume1
30 Day Avg. Volume104
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.70
Price to Sales (P/S)0.62
P/FCF Ratio21.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.45Price Target Upside19.55% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)1.33
Revenue Forecast (FY)€3.12B
Bulls Say, Bears Say
Bulls Say
Diversified Recurring Consumables And Technology ModelA broad portfolio spanning replenishment-driven consumables, implants, equipment, software and services gives Dentsply Sirona multiple revenue streams. Recurring procedure-related demand and its installed equipment base can support repeat purchases and customer relationships beyond individual capital-investment cycles.
Wellspect Growth Supported By New Products And ExpansionWellspect's 7.1% growth demonstrates that targeted product launches and geographic expansion can produce gains despite broader company pressure. Continued adoption of recent products provides evidence of an active innovation pipeline and a potentially durable source of mix improvement.
Positive Operating And Free Cash FlowPositive operating cash flow in every period shown, together with positive trailing free cash flow, gives the business internally generated funding for investment and obligations. Although cash generation is not yet sufficient to offset all earnings concerns, it provides a meaningful operating cushion.
Bears Say
Persistent Revenue ContractionRevenue pressure has persisted across several years and continued in the latest quarter, indicating a broad growth challenge rather than a single temporary variance. Sustained contraction can reduce operating leverage, weaken customer momentum and make the return-to-growth plan harder to execute.
Ongoing Losses And Weak ProfitabilityNegative net margins and repeated net losses show that the company has not yet converted its substantial product portfolio into durable bottom-line profitability. This limits retained capital for reinvestment and leaves results more dependent on operational improvement and recovery in demand.
Elevated Leverage Limits Financial FlexibilityDebt materially exceeds equity, and the balance sheet is less conservative than in 2021–2023. Elevated leverage can constrain capital allocation, increase the importance of maintaining cash generation and reduce flexibility if weak earnings persist or additional investment is required.
DENTSPLY SIRONA News
1XRAY FAQ
What was DENTSPLY SIRONA Inc’s price range in the past 12 months?
DENTSPLY SIRONA Inc lowest stock price was €5.00 and its highest was €18.00 in the past 12 months.
What is DENTSPLY SIRONA Inc’s market cap?
DENTSPLY SIRONA Inc’s market cap is €1.76B.
When is DENTSPLY SIRONA Inc’s upcoming earnings report date?
DENTSPLY SIRONA Inc’s upcoming earnings report date is Oct 29, 2026 which is in 41 days.
How were DENTSPLY SIRONA Inc’s earnings last quarter?
DENTSPLY SIRONA Inc released its earnings results on Aug 06, 2026. The company reported €0.446 earnings per share for the quarter, beating the consensus estimate of €0.298 by €0.147.
Is DENTSPLY SIRONA Inc overvalued?
According to Wall Street analysts DENTSPLY SIRONA Inc’s price is currently Undervalued.
Does DENTSPLY SIRONA Inc pay dividends?
DENTSPLY SIRONA Inc does not currently pay dividends.
What is DENTSPLY SIRONA Inc’s EPS estimate?
DENTSPLY SIRONA Inc’s EPS estimate is 0.27.
How many shares outstanding does DENTSPLY SIRONA Inc have?
DENTSPLY SIRONA Inc has 199,353,880 shares outstanding.
What happened to DENTSPLY SIRONA Inc’s price movement after its last earnings report?
DENTSPLY SIRONA Inc reported an EPS of €0.446 in its last earnings report, beating expectations of €0.298. Following the earnings report the stock price went down -10.533%.
Which hedge fund is a major shareholder of DENTSPLY SIRONA Inc?
Currently, no hedge funds are holding shares in IT:1XRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DENTSPLY SIRONA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€11.45 (19.55% Upside)
€11.45 (19.55% Upside)
Blogger Sentiment
Neutral
IT:1XRAY Sentiment 75%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth €444.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.25%
12-Months-Change
Fundamentals
Return on Equity
6.23%
Trailing 12-Months
Asset Growth
-14.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
DENTSPLY SIRONA Inc
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.
1XRAY Company Deck
1XRAY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.View all IT:1XRAY earnings summaries1XRAY Net sales Breakdown
15.71% Equipment & Instruments
12.45% CAD/CAM
39.92% Essential Dental Solutions
6.17% Orthodontics
16.93% Implants & Prosthetics
8.83% Wellspect Healthcare
1XRAY Stock 12 Month Forecast
Average Price Target
€11.45
▲(19.55% Upside)